Clinical Trial Update: MEDI-551 as Maintenance Therapy After Allogeneic Stem Cell Transplant in Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial investigating MEDI-551 as maintenance therapy after allogeneic stem cell transplantation in multiple myeloma; study terminated with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• MEDI-551 (inebilizumab)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Multiple Myeloma | Phase 2 | Status: TERMINATED | Results posted: 2018-05-29